4/23
08:12 am
rhhby
Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types [Yahoo! Finance]
Low
Report
Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types [Yahoo! Finance]
4/23
08:00 am
rhhby
Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types
Low
Report
Health Canada authorizes Tecentriq® SC (atezolizumab, solution for subcutaneous injection), the first cancer immunotherapy subcutaneous injection, for multiple cancer types
4/19
04:30 pm
rhhby
FDA Roundup: April 19, 2024 [Yahoo! Finance]
Medium
Report
FDA Roundup: April 19, 2024 [Yahoo! Finance]
4/19
12:14 pm
rhhby
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion [Yahoo! Finance]
Low
Report
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion [Yahoo! Finance]
4/19
01:03 am
rhhby
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer [Yahoo! Finance]
Low
Report
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer [Yahoo! Finance]
4/19
01:03 am
rhhby
FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer [Yahoo! Finance]
Low
Report
FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer [Yahoo! Finance]
4/18
05:19 pm
rhhby
FDA approves Roche's Alecensa for early stage ALK+ lung cancer [Seeking Alpha]
Low
Report
FDA approves Roche's Alecensa for early stage ALK+ lung cancer [Seeking Alpha]
4/18
04:44 pm
rhhby
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer [Yahoo! Finance]
Low
Report
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer [Yahoo! Finance]
4/18
04:35 pm
rhhby
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Low
Report
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
4/17
02:13 am
rhhby
Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS [Yahoo! Finance]
Medium
Report
Roche's subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS [Yahoo! Finance]
4/17
02:06 am
rhhby
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
Medium
Report
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
4/15
01:23 am
rhhby
Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study [Yahoo! Finance]
Low
Report
Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study [Yahoo! Finance]
4/15
01:10 am
rhhby
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
Low
Report
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
4/15
01:06 am
rhhby
[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study [Yahoo! Finance]
Low
Report
[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study [Yahoo! Finance]
4/10
09:15 am
rhhby
NCCN and Flatiron Health Announce Collaboration to Improve Cancer Care Quality with Real-World Data [Yahoo! Finance]
Low
Report
NCCN and Flatiron Health Announce Collaboration to Improve Cancer Care Quality with Real-World Data [Yahoo! Finance]
4/10
01:00 am
rhhby
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Low
Report
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
4/10
01:00 am
rhhby
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
Low
Report
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
4/8
08:14 am
rhhby
Hinge Bio Presents Preclinical Data from its GEM-DIMER Program Targeting B Cell Depletion at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Low
Report
Hinge Bio Presents Preclinical Data from its GEM-DIMER Program Targeting B Cell Depletion at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
4/5
05:18 am
rhhby
Should Weakness in Roche Holding AG's (VTX:ROG) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? [Yahoo! Finance]
Low
Report
Should Weakness in Roche Holding AG's (VTX:ROG) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? [Yahoo! Finance]
4/4
02:34 am
rhhby
BioPorto Announces Annual Results for 2023 [Yahoo! Finance]
Low
Report
BioPorto Announces Annual Results for 2023 [Yahoo! Finance]
4/3
08:53 am
rhhby
Genprex expands clinical trial sites for study to treat small cell lung cancer [Seeking Alpha]
Low
Report
Genprex expands clinical trial sites for study to treat small cell lung cancer [Seeking Alpha]
4/1
01:51 pm
rhhby
The Inner Circle acknowledges Elin Barth Berg as a Distinguished Healthcare Professional [Yahoo! Finance]
Low
Report
The Inner Circle acknowledges Elin Barth Berg as a Distinguished Healthcare Professional [Yahoo! Finance]
4/1
11:47 am
rhhby
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/28
06:36 am
rhhby
Affimed Reports 2023 Financial Results and Operational Progress [Yahoo! Finance]
Low
Report
Affimed Reports 2023 Financial Results and Operational Progress [Yahoo! Finance]
3/27
12:55 pm
rhhby
Do you have seasonal allergies? Here's how to find out and what to do [CNN]
Low
Report
Do you have seasonal allergies? Here's how to find out and what to do [CNN]